Newborns suffering from ultra-rare and fatal genetic disorder now have chance at life

By Team VIVA! | February 23, 2011

Newborns with the ultra-rare and fatal genetic disorder – molybdenum cofactor deficiency (MoCD) Type A – now have a chance at life after Alexion Pharmaceuticals, Inc. purchased the assets and patents from Orphatec Pharmaceuticals GmbH, in order to accelerate the development of an investigational therapy to cure the fatal disorder.  MoCD Type A is characterised…

Read More